Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

Rhea-AI Summary

Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced its participation in Citi's 2024 Global Healthcare Conference. The company's management will engage in a fireside chat on December 3, 2024, at 7:15 a.m. PT / 10:15 a.m. ET / 3:15 p.m. GMT. An audio webcast will be available through the company's investor website and archived for 30 days.

Jazz Pharmaceuticals is a global biopharma company focusing on developing life-changing medicines for serious diseases. The company maintains a diverse portfolio of marketed medicines for sleep disorders and epilepsy, along with cancer treatments. Based in Dublin, Ireland, Jazz operates research, development, and manufacturing facilities across multiple countries.

DUBLIN, Nov. 19, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 3, 2024, at 7:15 a.m. PT / 10:15 a.m. ET / 3:15 p.m. GMT.

An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be archived on the website for 30 days.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts: 

Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media: 
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-citis-2024-global-healthcare-conference-302310546.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When is Jazz Pharmaceuticals (JAZZ) participating in Citi's 2024 Healthcare Conference?

Jazz Pharmaceuticals will participate in a fireside chat at Citi's 2024 Global Healthcare Conference on December 3, 2024, at 7:15 a.m. PT / 10:15 a.m. ET / 3:15 p.m. GMT.

Where can I watch Jazz Pharmaceuticals' (JAZZ) presentation at Citi's 2024 Healthcare Conference?

The audio webcast will be available through the Investors section of Jazz Pharmaceuticals' website at investor.jazzpharma.com/investors/events-presentations, with a replay available for 30 days.

What are the main therapeutic areas for Jazz Pharmaceuticals (JAZZ)?

Jazz Pharmaceuticals focuses on sleep disorders, epilepsy, and cancer treatments, with a growing portfolio of marketed medicines and an innovative pipeline in oncology and neuroscience.